Retinal Toxicity Services
Accelerated in vitro evaluation of retinal toxicity. Newcells offers a fast and reliable retinal drug toxicity in vitro testing service using complex models developed in house: retinal organoids and RPE. The retinal toxicity service evaluates how new compounds affect cell viability, following photoreceptor degeneration or loss of RPE barrier function including outer segment photoreceptor phagocytosis. We also offer the comparison of several time points during differentiation. Our retinal toxicity service is fast, giving our clients insights into the ocular toxicity profile of their compounds and allowing them to evaluate possible rescue strategies.
Service Outputs
- Rapid retinal toxicity evaluation of compounds in iPSC-derived retinal organoids or RPE cells
- Qualitative immunofluorescence on frozen retinal organoid sections using key markers
- Time point comparisons
- Assessment of the composition of retinal ganglion cells, photoreceptors, amacrine, horizontal cells and Muller glia using imaging techniques
- Evaluation of photoreceptor and RPE degeneration
- Analysis of loss of RPE barrier function & loss of phagocytosis of photoreceptor outer segment
Details
- Cell viability assay
- Key marker analysis
- Qualitative immunofluorescence
- Gene expression
- Photoreceptor degeneration
- Phagocytosis of photoreceptor outer segment
- Transmission (TEM) and Scanning (SEM) electron microscopy
- Human retinal organoids
- Human retinal pigment epithelial (RPE) cells
- Derived from WT or CRISPR/Cas9 gene edited iPSCs
- Rapid
- 2-6 months
Newcells Retinal Models
Accelerate your lead compound selection by understanding their mode of action in functional retinal tissue
- Recapitulate the architecture and function of the human retina
- Evaluate novel drugs safety profile in vitro
- Accelerate drug discovery & replace animal experiments
Customer reviews
No reviews were found for Retinal Toxicity Services. Be the first to review!